Staging classification for cancer of the ovary, fallopian tube, and peritoneum

By J. Prat. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2014

1,194 citations recorded by the source corpus.

Subfields: Genetics, Obstetrics and Gynecology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/532b879e806db858a1a7770b9f68dac6f2cbd344

Citations in the corpus

• Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer (2019, neutral): “Any residual disease 76/250 (30) 89/253 (35) 83/261 (32)”
• ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019, neutral): “This evidence also forms the basis for recommendations on uniform staging of low-stage HGSC in cases that are left to the pathologist’s and clinician’s discretion in the current FIGO system [20, 21], resulting in potential for identical cases to be staged differently [6].”